Morgan Stanley starts Dyne Therapeutics stock with Overweight, bullish on FORCE platform By…
On Tuesday, Morgan Stanley began coverage on Dyne Therapeutics (NASDAQ:DYN) stock, assigning an Overweight rating and setting a price target of $40.00. The firm's assessment hinges on the promising early data from the company's leading drug…
